Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Detailed results from Biogen Idec and AbbVie's pivotal Phase 3 DECIDE study further define the efficacy and safety profile of ZINBRYTA™ (daclizumab high-yield process)
Common and Rare Manifestations of Neuromyelitis Optica Spectrum Disorder.
Gordon Research Conference on Notch Signaling in Development, Regeneration & Disease
Disease Modifying Therapies Modulate Cardiovascular Risk Factors in Multiple Sclerosis Patients.
[Neurophysiology in Guillain-Barré syndrome].
AB Science announces recruitment of first patient in phase 3 study of masitinib in progressive multiple sclerosis
Novantrone
Developmental Origin of Oligodendrocyte Lineage Cells Determines Response to Demyelination and Susceptibility to Age-Associated Functional Decline.
Enhancement of Chemotactic Cell Aggregation by Haptotactic Cell-To-Cell Interaction.
Predictors and dynamics of postpartum relapses in women with multiple sclerosis.
Social Support in Relation to Fatigue Symptoms Among Patients with Multiple Sclerosis.
Clinically isolated syndromes.
Dimethyl fumarate protection against collagen II degradation.
FGF-1 Triggers Pannexin-1 Hemichannel Opening in Spinal Astrocytes of Rodents and Promotes Inflammatory Responses in Acute Spinal Cord Slices.
The low EOMES/TBX21 molecular phenotype in multiple sclerosis reflects CD56+ cell dysregulation and is affected by immunomodulatory therapies.
Multiple sclerosis and neuromyelitis optica spectrum disorders: some similarities in two distinct diseases.
Tolerability and pharmacokinetics of delayed-release dimethyl fumarate administered with and without aspirin in healthy volunteers.
Multiple sclerosis review.
LINGO-1, A TRANSMEMBRANE SIGNALING PROTEIN, INHIBITS OLIGODENDROCYTE DIFFERENTIATION AND MYELINATION THROUGH INTERCELLULAR SELF-INTERACTIONS.
Genzyme receives positive CHMP opinion for LEMTRADA™ (alemtuzumab) in Europe
Personality in multiple sclerosis (MS): impact on health, psychological well-being, coping, and overall quality of life.
Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.
Neuro-Immune Interactions at Barrier Surfaces.
New Data Show Strong, Sustained Effects of TECFIDERA® (Dimethyl Fumarate) in Newly-Diagnosed and Early Disease Course Multiple Sclerosis Patients
Promising Oral Compounds for the Treatment of Multiple Sclerosis: A Glance into the Future.

Pages